Clinical Trial Detail

NCT ID NCT02196857
Title Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Azacitidine + Sorafenib

Age Groups: adult

No variant requirements are available.